Protalix BioTherapeutics (PLX) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Protalix BioTherapeutics (PLX) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Protalix BioTherapeutics | 192.04 Mn | 181.24 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 613.06% |
| Dec 31, 2025 | -248.47% |
| Sep 30, 2025 | 511.14% |
| Jun 30, 2025 | 110.91% |
| Mar 31, 2025 | -133.49% |
| Dec 31, 2024 | 211.23% |
| Sep 30, 2024 | 257.60% |
| Jun 30, 2024 | 52.06% |
| Mar 31, 2024 | 77.17% |
| Dec 31, 2023 | -986.61% |
| Sep 30, 2023 | -111.43% |
| Jun 30, 2023 | 617.69% |
| Mar 31, 2023 | 2.46% |
| Dec 31, 2022 | 10.01% |
| Sep 30, 2022 | 33.13% |
| Jun 30, 2022 | -133.33% |
| Mar 31, 2022 | 60.78% |
| Dec 31, 2021 | -35.69% |
| Sep 30, 2021 | 62.22% |
| Jun 30, 2021 | -93.98% |